Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Trial Profile

A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Reldesemtiv (Primary)
  • Indications Muscular atrophy
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 31 Oct 2018 Status changed to discontinued due to Lack of efficacy determined at interim analysis
    • 05 Oct 2018 According to an Astellas Pharma, status changed from recruiting to suspended, because Independent Data Monitoring Committee determined that the pre-defined criteria for lack of efficacy of reldesemtiv had been met.
    • 26 Sep 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top